SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues

The genomic landscape of mantle cell lymphoma (MCL) includes frequent alterations of TP53, ATM, CCND1 and KMT2D. Thus far, the mutational landscape provides little information for treatment stratification. We characterized a cohort of MCL by targeted next generation sequencing and discovered SAMHD1 as a novel recurrently mutated gene (8.5% of investigated cases, 4/47 samples). Furthermore, we provide evidence of in vitro resistance of SAMHD1 mutated patient-derived MCL cells to cytarabine and fludarabine.

[1]  A. Rosenwald,et al.  The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial , 2020, International journal of cancer.

[2]  E. Giné,et al.  Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes. , 2020, Blood.

[3]  A. Schuh,et al.  SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP , 2020, Cell reports.

[4]  D. Rossi,et al.  KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study , 2019, Haematologica.

[5]  L. Kaderali,et al.  Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML , 2019, Nature Communications.

[6]  F. Pozzo,et al.  Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia , 2018, Blood.

[7]  E. Campo,et al.  Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. , 2018, Blood.

[8]  Andrzej K. Oleś,et al.  Supplementary figures and tables , 2017 .

[9]  R. Siebert,et al.  SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia , 2018, Blood Cancer Journal.

[10]  Allyson E. Koyen,et al.  SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. , 2017, Cell reports.

[11]  S. Lehmann,et al.  Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies , 2017, Nature Medicine.

[12]  L. Kaderali,et al.  SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia , 2016, Nature Medicine.

[13]  W. Klapper,et al.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.

[14]  S. Malek,et al.  A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia , 2016, Clinical Cancer Research.

[15]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[16]  F. Lasitschka,et al.  SAMHD1's protein expression profile in humans , 2015, Journal of leukocyte biology.

[17]  Dereje D. Jima,et al.  The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. , 2014, Blood.

[18]  D. Bentley,et al.  SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. , 2014, Blood.

[19]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[20]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[21]  Jonathan C. Fuller,et al.  Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response , 2009, Nature Genetics.

[22]  E. Hoster,et al.  European mantle cell lymphoma network , 2008 .